Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q93070

UPID:
NAR4_HUMAN

ALTERNATIVE NAMES:
ADP-ribosyltransferase C2 and C3 toxin-like 4; Dombrock blood group carrier molecule; Mono(ADP-ribosyl)transferase 4; NAD(P)(+)--arginine ADP-ribosyltransferase 4

ALTERNATIVE UPACC:
Q93070; Q9BZ50; Q9BZ51; Q9HB06

BACKGROUND:
The protein Ecto-ADP-ribosyltransferase 4, with its array of alternative names including Mono(ADP-ribosyl)transferase 4 and Dombrock blood group carrier molecule, signifies its importance in the biological landscape. It functions as an ADP-ribosyltransferase, a type of enzyme that contributes to the regulation of protein functions by adding ADP-ribose to target proteins, a process critical for maintaining cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ecto-ADP-ribosyltransferase 4 offers a promising pathway towards the development of novel therapeutic approaches. By elucidating its role in cellular mechanisms, researchers can identify new opportunities for intervention in diseases where this protein's activity is dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.